Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTR@PID 054 long-term follow-up study of bintrafusp alfa in cancer
jRCT2031210560Completed
- Sponsor
- Merck KGaA
- Start
- Jan 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Open-label, single-arm trial of bintrafusp alfa in cancer, sponsored by Merck KGaA. Primary endpoint: Occurrence of Adverse Events and Treatment-Related Adverse Events. Started Jan 2022; status: completed.
02
Drugs
bintrafusp alfa
03
Conditions
cancer
Beyond the preview
Go deeper on jRCT2031210560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210560.